BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31275450)

  • 41. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer.
    Esajas MD; Duk JM; de Bruijn HW; Aalders JG; Willemse PH; Sluiter W; Pras B; ten Hoor K; Hollema H; van der Zee AG
    J Clin Oncol; 2001 Oct; 19(19):3960-6. PubMed ID: 11579117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy.
    Ogino I; Nakayama H; Okamoto N; Kitamura T; Inoue T
    Int J Gynecol Cancer; 2006; 16(3):1094-100. PubMed ID: 16803491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative squamous cell carcinoma antigen and albumin serum levels predict the survival of patients with stage T1-3N0M0 esophageal squamous cell carcinoma: a retrospective observational study.
    Wu LL; Liu X; Huang W; Lin P; Long H; Zhang LJ; Ma GW
    J Cardiothorac Surg; 2020 May; 15(1):115. PubMed ID: 32456707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Squamous Cell Carcinoma Antigen in the Follow-up of Patients With Head and Neck Cancer.
    Schepens EJA; Al-Mamgani A; Karssemakers LHE; van den Broek D; van den Brekel MWM; Lopez-Yurda M
    Otolaryngol Head Neck Surg; 2024 Feb; 170(2):422-430. PubMed ID: 37694613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum miR-638 Combined with Squamous Cell Carcinoma-Related Antigen as Potential Screening Biomarkers for Cervical Squamous Cell Carcinoma.
    Zheng S; Li R; Liang J; Wen Z; Huang X; Du X; Dong S; Zhu K; Chen X; Liu D; Wu J; Liu Y; Zou X; Wang Y; Li J; Zeng F; Feng L; Yang G; Jing C
    Genet Test Mol Biomarkers; 2020 Apr; 24(4):188-194. PubMed ID: 32216635
    [No Abstract]   [Full Text] [Related]  

  • 47. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.
    Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Gunji Y; Kobayashi S; Hayashi H; Ochiai T
    Surgery; 2003 May; 133(5):486-94. PubMed ID: 12773976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of squamous cell carcinoma antigen in patients with uterine cervical carcinoma.
    Bhatavdekar JM; Ghosh N; Shukla MK; Balar DB; Bhaduri A; Karelia NH; Shah NG; Trivedi SN
    Tumori; 1988 Apr; 74(2):221-5. PubMed ID: 3368976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.
    Wen YF; Cheng TT; Chen XL; Huang WJ; Peng HH; Zhou TC; Lin XD; Zeng LS
    PLoS One; 2018; 13(10):e0204334. PubMed ID: 30303986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis.
    Liu Z; Shi Y; Meng W; Liu Y; Yang K; Wu S; Peng Z
    Arch Gynecol Obstet; 2014 Feb; 289(2):373-82. PubMed ID: 23959090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
    Jing Z; Heng W; Aiping D; Yafei Q; Shulan Z
    Int J Gynecol Cancer; 2013 Oct; 23(8):1465-9. PubMed ID: 24247658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
    Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
    Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
    J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-Dependent Squamous Cell Carcinoma Antigen in Prediction of Relapse and Death of Patients With Cervical Cancer.
    Chang C; Chen J; Huang CH; Lee WY; Hsu LC; Chiang AJ
    J Low Genit Tract Dis; 2020 Jan; 24(1):38-42. PubMed ID: 31860573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma.
    Chen P; Jiao L; Ren F; Wang DB
    BMC Cancer; 2020 May; 20(1):423. PubMed ID: 32410650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
    Lee JH; Lee SW; Kim JR; Kim YS; Yoon MS; Jeong S; Kim JH; Lee JY; Eom KY; Jeong BK; Lee SH
    Gynecol Oncol; 2017 Dec; 147(3):577-584. PubMed ID: 29110878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway.
    Li B; Guo X; Li N; Chen Q; Shen J; Huang X; Huang G; Wang F
    Cell Oncol (Dordr); 2020 Jun; 43(3):489-503. PubMed ID: 32301035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
    Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
    Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.